Do you want to read an article? Please log in or register.
Guidance for Fecal Microbiota Transplantation Trials in Ulcerative Colitis: The Second ROME Consensus Conference
Inflammatory Bowel Disease
RECOMMENDED
Related content
Inflammatory Bowel Disease
Fecal Microbiota Transplantation Outcome and Gut Microbiota Composition in Ulcerative Colitis: a Systematic Review and Meta-analysis
Clin Gastroenterol Hepatol
Bénard MV, de Goffau MC, Blonk J, Hugenholtz F, van Buuren J, Paramsothy S, Kaakoush NO, D'Haens GRAM, Borody TJ, Kamm MA, Ponsioen CY
doi: 10.1016/j.cgh.2024.10.001
Inflammatory Bowel Disease
Novel Microbial Engraftment Trajectories following Microbiota Transplantation Therapy in Ulcerative Colitis
J Crohns Colitis
Moutsoglou D, Syal A, Lopez S, Nelson EC, Chen L, Kabage AJ, Fischer M, Khoruts A, Vaughn BP, Staley C
doi: 10.1093/ecco-jcc/jjae142
Inflammatory Bowel Disease
Safety comparison of single-donor and pooled fecal microbiota transfer product preparation in ulcerative colitis: systematic review and meta-analysis
BMC Gastroenterol
Laperrousaz B, Levast B, Fontaine M, Nancey S, Dechelotte P, Doré J, Lehert P
doi: 10.1186/s12876-024-03487-2
Further Publications
Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis
Inflamm Bowel Dis
Chhibba T, Frolkis A, Stein LR, Lee S, Schill K, Mitevska E, Judge AK, Martin ML, Martin M, Novak KL, Lu C, Ingram RJM, Chan MM, Shukla T, Seow CH, Kaplan GG, Ananthakrishnan AN, Panaccione R, Ma C
doi: 10.1093/ibd/izaf012
Inflammatory Bowel Disease
Intestinal Ultrasound, Fecal Calprotectin, and Their Combination to Predict Endoscopic Mucosal Healing in Ulcerative Colitis: A Real-Life Cross-Sectional Study
Inflamm Bowel Dis
Yzet C, Meudjo E, Brazier F, Hautefeuille V, Moreau C, Robert C, Decrombecque C, Sarba R, Pichois R, Richard N, Meynier J, Fumery M
doi: 10.1093/ibd/izae145
RECOMMENDED
Inflammatory Bowel Disease
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Lancet Gastroenterol Hepatol
ACCURE Study Group
doi: 10.1016/S2468-1253(25)00026-3
COMMENTED
Inflammatory Bowel Disease
Efficacy and Safety of Anthocyanin-Rich Extract in Patients with Ulcerative Colitis: A Randomized Controlled Trial
★ 3
Recommended and commented by
Prof. Dr Stephan Vavricka, Faculty Member
Nutrients
Biedermann L, Doulberis M, Schreiner P, Nielsen OH, The FO, Brand S, Burk S, Hruz P, Juillerat P, Krieger-Grübel C, Leu K, Leventhal GE, Misselwitz B, Scharl S, Schoepfer A, Seibold F, Herfarth H, Rogler G
doi: 10.3390/nu16234197
Inflammatory Bowel Disease
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)
J Crohns Colitis
Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB
doi: 10.1093/ecco-jcc/jjaf060
Inflammatory Bowel Disease
Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial
Lancet Gastroenterol Hepatol
Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P
doi: 10.1016/S2468-1253(24)00200-0